Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CLIMB BIO Aktie jetzt für 0€ handeln | |||||
18.06. | Climb Bio Names Edgar Charles CMO, Cindy Driscoll SVP-Finance | - | RTTNews | ||
18.06. | Climb Bio appoints Edgar D. Charles as Chief Medical Officer | 1 | Seeking Alpha | ||
18.06. | Climb Bio appoints new chief medical officer and finance executive | 1 | Investing.com | ||
18.06. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
18.06. | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | 182 | GlobeNewswire (Europe) | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
06.06. | Oppenheimer initiates coverage on Climb Bio stock with outperform rating | 1 | Investing.com | ||
06.06. | Oppenheimer beginnt Berichterstattung über Climb Bio-Aktie mit Outperform-Rating | 1 | Investing.com Deutsch | ||
05.06. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.06. | Clym: ARD Money Maker portraitiert Solarpunk-Macher Clym | 1 | GamesWirtschaft | ||
22.05. | BTIG sets Climb Bio stock Buy rating, $7 target | 2 | Investing.com | ||
19.05. | Climb Bio, Inc.: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 110 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases,... ► Artikel lesen | |
14.05. | Climb Bio GAAP EPS of -$0.31 | 1 | Seeking Alpha | ||
14.05. | Climb Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
14.05. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.04. | Climb Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
25.03. | Climb Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.03. | Climb Bio, Inc.: Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates | 572 | GlobeNewswire (Europe) | Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus... ► Artikel lesen | |
25.03. | Climb Bio, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
24.02. | Climb Bio, Inc.: Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer | 367 | GlobeNewswire (Europe) | WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished... ► Artikel lesen | |
10.01. | Climb Bio enters licensing deal with Mabworks for CLYM116 development | 1 | Pharmaceutical Technology |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
MODERNA | 23,305 | +0,17 % | Laboratorios Rovi: FDA approves Moderna vaccine for RSV in adults aged 18 to 59 | ||
REGENERON PHARMACEUTICALS | 444,00 | -0,22 % | Bayer, Regeneron get EU nod for Eylea's label extension | ||
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen |